Rinri Therapeutics is a private biotechnology company developing the world’s first regenerative cell therapies for hearing loss. The company’s pioneering technology seeks to reverse sensorineural hearing loss (SNHL), the leading form of deafness, through the repair and regeneration of the damaged cytoarchitecture of the inner ear. There are currently no pharmacological treatment options for SNHL patients.